TG Therapeutics Inc (NASDAQ:TGTX) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 16,118,224 shares, a decline of 15.0% from the February 15th total of 18,973,302 shares. Currently, 41.3% of the shares of the company are short sold. Based on an average daily volume of 1,617,817 shares, the short-interest ratio is currently 10.0 days.

In other news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 16.70% of the company’s stock.

How to Become a New Pot Stock Millionaire

Hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors grew its holdings in shares of TG Therapeutics by 24.2% during the second quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 5,167 shares during the last quarter. Northern Trust Corp raised its position in shares of TG Therapeutics by 29.0% during the second quarter. Northern Trust Corp now owns 598,626 shares of the biopharmaceutical company’s stock valued at $6,016,000 after buying an additional 134,463 shares during the last quarter. Vanguard Group Inc. raised its position in shares of TG Therapeutics by 14.3% during the second quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after buying an additional 255,844 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in shares of TG Therapeutics by 7.5% during the second quarter. Parametric Portfolio Associates LLC now owns 85,612 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 5,958 shares during the last quarter. Finally, Voya Investment Management LLC raised its position in shares of TG Therapeutics by 40.2% during the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 6,463 shares during the last quarter. 50.63% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics (NASDAQ:TGTX) opened at $16.55 on Monday. The stock has a market cap of $1,170.00, a price-to-earnings ratio of -8.62 and a beta of 1.40. TG Therapeutics has a 52 week low of $7.25 and a 52 week high of $17.35.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.46). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 137.47%. equities analysts predict that TG Therapeutics will post -1.69 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on TGTX shares. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. B. Riley initiated coverage on shares of TG Therapeutics in a research report on Friday, December 1st. They issued a “buy” rating and a $21.50 target price on the stock. BidaskClub lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. Raymond James Financial restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $24.60.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/03/12/short-interest-in-tg-therapeutics-inc-tgtx-declines-by-15-0.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.